Total Payments
$25,275
2024 Payments
$4,007
Companies
12
Transactions
150
Medicare Patients
3,177
Medicare Billing
$489,743
Payment Breakdown by Category
Other$21,563 (85.3%)
Food & Beverage$3,052 (12.1%)
Travel$631.79 (2.5%)
Education$28.99 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $21,563 | 37 | 85.3% |
| Food and Beverage | $3,052 | 106 | 12.1% |
| Travel and Lodging | $631.79 | 6 | 2.5% |
| Education | $28.99 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $13,616 | 52 | $0 (2024) |
| Allergan, Inc. | $10,343 | 45 | $0 (2021) |
| ViiV Healthcare Company | $413.56 | 17 | $0 (2024) |
| Janssen Biotech, Inc. | $246.32 | 14 | $0 (2022) |
| Gilead Sciences, Inc. | $147.28 | 7 | $0 (2023) |
| Theravance Biopharma Inc. | $133.67 | 2 | $0 (2017) |
| Biosense Webster, Inc. | $119.09 | 1 | $0 (2018) |
| Merck Sharp & Dohme Corporation | $94.73 | 5 | $0 (2019) |
| Shionogi Inc | $63.23 | 2 | $0 (2024) |
| Paratek Pharmaceuticals, Inc. | $39.34 | 2 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $4,007 | 16 | ABBVIE INC. ($3,827) |
| 2023 | $2,665 | 14 | ABBVIE INC. ($2,494) |
| 2022 | $4,090 | 24 | ABBVIE INC. ($3,984) |
| 2021 | $4,198 | 18 | AbbVie Inc. ($3,270) |
| 2020 | $5,630 | 21 | Allergan, Inc. ($5,597) |
| 2019 | $243.33 | 15 | Allergan Inc. ($70.44) |
| 2018 | $299.55 | 10 | Biosense Webster, Inc. ($119.09) |
| 2017 | $4,142 | 32 | Allergan Inc. ($3,757) |
All Payment Transactions
150 individual payment records from CMS Open Payments — Page 1 of 6
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/21/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $22.89 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/19/2024 | ABBVIE INC. | TEFLARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/30/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $27.78 | General |
| Category: HIV | ||||||
| 10/23/2024 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $27.37 | General |
| Category: HIV | ||||||
| 10/08/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $24.00 | General |
| Category: HIV | ||||||
| 09/30/2024 | ABBVIE INC. | TEFLARO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $675.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/20/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $27.20 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/19/2024 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $28.35 | General |
| Category: Infections and Infectious Diseases | ||||||
| 06/13/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $29.34 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/06/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $10.03 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/04/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,250.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/13/2024 | ABBVIE INC. | TEFLARO (Drug), DALVANCE | Food and Beverage | In-kind items and services | $123.65 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/10/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $21.35 | General |
| Category: ANTIBIOTIC | ||||||
| 04/08/2024 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $33.45 | General |
| Category: HIV | ||||||
| 02/13/2024 | Paratek Pharmaceuticals, Inc. | NUZYRA (Drug) | Food and Beverage | In-kind items and services | $17.99 | General |
| Category: ANTIBIOTIC | ||||||
| 01/04/2024 | ABBVIE INC. | AVYCAZ (Drug), TEFLARO, DALVANCE | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: ANTI-INFECTIVE | ||||||
| 11/07/2023 | ABBVIE INC. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $562.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/03/2023 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $34.88 | General |
| Category: Infections and Infectious Diseases | ||||||
| 08/29/2023 | ABBVIE INC. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $562.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 08/15/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $21.64 | General |
| Category: ANTI-INFECTIVE | ||||||
| 07/27/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $34.24 | General |
| 06/27/2023 | ABBVIE INC. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $562.50 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/19/2023 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $18.54 | General |
| 06/14/2023 | ViiV Healthcare Company | DOVATO (Drug) | Food and Beverage | In-kind items and services | $25.87 | General |
| Category: HIV | ||||||
| 05/01/2023 | ABBVIE INC. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 5 | 868 | 1,905 | $275,563 | $144,319 |
| 2022 | 5 | 706 | 1,427 | $209,452 | $104,343 |
| 2021 | 5 | 712 | 1,324 | $201,858 | $103,769 |
| 2020 | 6 | 891 | 1,792 | $263,691 | $137,312 |
Total Patients
3,177
Total Services
6,448
Medicare Billing
$489,743
Procedure Codes
21
All Medicare Procedures & Services
21 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 450 | 1,416 | $168,513 | $92,533 | 54.9% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 310 | 339 | $77,709 | $35,785 | 46.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 65 | 85 | $14,648 | $8,541 | 58.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 22 | 44 | $7,656 | $4,479 | 58.5% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 21 | 21 | $7,037 | $2,982 | 42.4% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 371 | 1,047 | $124,401 | $62,215 | 50.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 231 | 237 | $53,729 | $26,273 | 48.9% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 39 | 41 | $13,674 | $6,868 | 50.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 46 | 64 | $11,036 | $5,423 | 49.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 19 | 38 | $6,612 | $3,565 | 53.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 355 | 923 | $109,484 | $56,544 | 51.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 233 | 247 | $56,192 | $28,588 | 50.9% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 59 | 59 | $19,780 | $9,927 | 50.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 50 | 64 | $11,008 | $5,670 | 51.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 15 | 31 | $5,394 | $3,041 | 56.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 437 | 1,296 | $153,487 | $80,607 | 52.5% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2020 | 279 | 286 | $65,291 | $33,813 | 51.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 73 | 73 | $24,455 | $12,450 | 50.9% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 68 | 81 | $13,932 | $7,288 | 52.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 13 | 24 | $4,176 | $2,048 | 49.0% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2020 | 21 | 32 | $2,350 | $1,106 | 47.1% |
About Dr. Daniel Kaswan, MD
Dr. Daniel Kaswan, MD is a Infectious Disease healthcare provider based in Aventura, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 03/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1942326418.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Daniel Kaswan, MD has received a total of $25,275 in payments from pharmaceutical and medical device companies, with $4,007 received in 2024. These payments were reported across 150 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($21,563).
As a Medicare-enrolled provider, Kaswan has provided services to 3,177 Medicare beneficiaries, totaling 6,448 services with total Medicare billing of $489,743. Data is available for 4 years (2020–2023), covering 21 distinct procedure/service records.
Ad
Practice Information
- Specialty Infectious Disease
- Location Aventura, FL
- Active Since 03/22/2007
- Last Updated 10/29/2009
- Taxonomy Code 207RI0200X
- Entity Type Individual
- NPI Number 1942326418
Products in Payments
- AVYCAZ (Drug) $11,494
- DALVANCE (Drug) $6,442
- TEFLARO (Drug) $5,954
- DOVATO (Drug) $205.05
- VIBATIV (Drug) $133.67
- Symtuza (Drug) $119.89
- Carto 3 System (Device) $119.09
- TRIUMEQ (Drug) $108.35
- CABENUVA (Biological) $100.16
- PREZCOBIX (Drug) $73.20
- Fetroja (Drug) $63.23
- SYMTUZA (Drug) $53.23
- Mavyret (Drug) $40.45
- NUZYRA (Drug) $39.34
- ISENTRESS (Drug) $38.38
- MAVYRET (Drug) $27.37
- PREVYMIS (Drug) $19.98
- NOXAFIL (Drug) $19.47
- REYATAZ (Drug) $17.64
- ZERBAXA (Drug) $16.90
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.